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Abstract
Background and Objectives Statin-induced changes in
high-density lipoprotein cholesterol (HDL-C) and low-
density lipoprotein cholesterol (LDL-C) are unrelated.
Many patients initiated on statins experience a paradoxical
decrease in HDL-C. The aim of this study was to evaluate
the association between a decrease in HDL-C and risk of
major adverse cardiovascular events (MACE).
Methods Data from 15,357 primary care patients initiated
on statins during 2004–2009 were linked with data from
mandatory national hospital, drug-dispensing, and cause-
of-death registers, and were grouped according to HDL-C
change: decreased C0.1 mmol/L, unchanged ±0.1 or
C0.1 mmol/L increased. To evaluate the association
between decrease in HDL-C and risk of MACE, a sample
of propensity score-matched patients from the decreased
and unchanged groups was created, using the latter group
as reference. MACE was defined as myocardial infarction,
unstable angina pectoris, ischaemic stroke, or cardiovas-
cular mortality. Cox proportional hazards models were
used to estimate relative risks.
Results HDL-C decreased in 20 %, was unchanged in
58%, and increased in 22 % of patients initiated on statin
treatment (96 % treated with simvastatin). The propensity
score-matched sample comprised 5950 patients with mean
baseline HDL-C and LDL-C of 1.69 and 4.53 mmol/L,
respectively. HDL-C decrease was associated with 56 %
higher MACE risk (hazard ratio 1.56; 95 % confidence
interval 1.12–2.16; p\ 0.01) compared with the unchan-
ged HDL-C group.
Conclusions Paradoxical statin-induced reduction in
HDL-C was relatively common and was associated with
increased risk of MACE.
Key Points
Of patients newly initiated on statin treatment, one-
fifth experienced a decrease in HDL-C.
This HDL-C decrease was associated with higher
risk of major adverse cardiovascular events
compared with unchanged HDL-C.
Statin induced HDL-C decrease might be more
hazardous than previously recognised and patients
should be monitored closely regarding potential
cardiovascular risk.
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1 Introduction
The role of high-density lipoprotein cholesterol (HDL-C)
as a potential risk factor in the development of cardiovas-
cular disease (CVD) is not fully understood. Epidemio-
logical studies have reported an association between HDL-
C single point measurements and risk of coronary heart
disease (which forms a large proportion of CVD) [1–3].
Some guidelines recommend an HDL-C target above
1.0 mmol/L for men and above 1.2 mmol/L for women, [4]
but such goals have also been questioned [5, 6]. Recent
studies with novel HDL-C-raising therapies have not
shown a clear preventive effect of increasing HDL-C on
risk of CVD. Treatment with one such agent, torcetrapib,
resulted in an increased risk of mortality and morbidity of
unknown mechanism, whereas potential favourable effects
of another agent, dalcetrapib, with respect to HDL-C were
possibly offset by other unfavourable effects [7, 8].
Statins show various degrees of low-density lipoprotein
cholesterol (LDL-C)-lowering and HDL-C-raising effects,
[9] where the action on HDL-C is independent of the
reduction in LDL-C [10]. Is has been indicated from a
meta-analysis that among statin-treated patients, HDL-C
levels are strongly and inversely associated with the risk of
major cardiovascular events [11]. Notably, a large pro-
portion of patients experienced a paradoxical decrease in
HDL-C following statin treatment initiation [10]. A recent
study reported an inverse association between the para-
doxical HDL-C decrease after initiation of statin therapy
and major adverse cardiovascular events in patients with
acute myocardial infarction [12]. It is possible that a
reduction in HDL-C is associated with suboptimal protec-
tion against cardiovascular events [13].
The aim of this observational study was to investigate
the association between paradoxical HDL-C decrease after
initiation of statin therapy and major adverse cardiovas-
cular events in a general primary care patient population.
2 Methods
The study protocol was reviewed and approved by the
regional research ethics committee in Uppsala, Sweden
(Reference number 2012/007) and registered at Clini-
calTrials.gov (clinical trial identifier NCT01551784).
This study linked data from electronic patient records to
hospital, drug-dispensing, and cause-of-death registers.
Information on blood lipids and patient characteristics was
extracted from primary care medical records [e.g. date of
birth, gender, body weight, blood pressure, number of
primary healthcare centre contacts, and diagnosis accord-
ing to International Classification of Diseases, 10th
revision, Clinical Modification (ICD-10-CM) codes) using
an established software system [14].
Data regarding morbidity and mortality were collected
from the Swedish National Patient Register, inpatient
(admission and discharge dates, and main and secondary
diagnoses) and outpatient hospital care (number of contacts
and diagnosis according to ICD-10-CM codes) registers,
and the Swedish National Cause-of-Death Register (date
and cause of death) [15]. Drug-dispensing data were col-
lected from the Swedish Prescribed Drug Register.
Data linkage was performed by the Swedish National
Board of Health and Welfare. The linked study database is
owned and managed by the Department of Public Health
and Caring Sciences, Uppsala University, Uppsala, Swe-
den. Personal identification numbers used to identify
included patients in all healthcare contacts and were
anonymised prior to further data processing.
The study population consisted of statin-naı¨ve patients
initiating a first statin treatment at 76 primary care centres
in Sweden. To facilitate a representative selection of pri-
mary care centres in Sweden, a mix of rural and urban
areas, public and private care providers, and small, mid-
sized, and large primary care centres (all using the same
electronic patient journal system) was included, corre-
sponding to approximately 7 % of the Swedish primary
care centres. Men and women were eligible for inclusion if
they were aged 18–85 years and were prescribed statins
[Anatomical Therapeutic Chemical (ATC): C10A A]
between 1 January 2004 and 31 December 2009. Patients
had to have HDL-C and LDL-C measurements recorded
within 12 months prior to the start of statin treatment as
well as a measurement after 10 days and within 12 months
on treatment; patients with cardiovascular events before the
first HDL-measurement on statin treatment were excluded.
Patients with an LDL-C lowering of no more than
0.5 mmol/L were also excluded due to insufficient statin
effect or indication of low compliance to statin treatment.
Further exclusion criteria were prior history of alcoholism
and on-going malignancy.
The date of first known statin dispense was defined as
start of statin treatment. The start of the observation period
for collecting endpoints was date of first HDL-C mea-
surement on statin treatment. The end of the study obser-
vation was 31 December 2011, the end of statin treatment,
or death. If a gap of more than 90 days was observed,
based on available dispensed drug data, the end of statin
treatment was defined as calculated days on last available
dispensed drug package plus an additional 25 % of days
based on the last dispensed drug pack size.
Two HDL-C groups were defined based on change in
between last HDL-C measurement prior statin treatment
and first HDL-C measurement on at least 14 days of statin
treatment: HDL-C decrease: more than 0.1 mmol/L and
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HDL-C unchanged group: ±0.1 mmol/L. In addition, a
group with more than 0.1 mmol/L increase in HDL-C was
defined to explore the effect of HDL-C increase.
The analysis was performed in two patient samples; the
matched sample, which included HDL-C decrease and
unchanged HDL-C patients who fulfilled the inclusion and
exclusion criteria and who could be propensity score
matched for baseline characteristics regarding propensity
of HDL-C decrease. The unmatched population used for
sub-group analyses comprised all patients who fulfilled the
inclusion and exclusion criteria.
The major adverse cardiovascular event (MACE) end-
point was a composite of hospitalisation for a primary
diagnosis for myocardial infarction (ICD-10, I21), unsta-
ble angina pectoris (ICD-10, I20.0), ischaemic stroke
(ICD-10, I63), or cardiovascular death (all primary causes
of death diagnosed with ICD-10 codes I00–I99).
Differences in baseline data between the two HDL-C
groups were tested by one-way ANOVA and Pearson’s chi-
square test according to the type of data. Differences
between groups were considered statistically significant
when p was less than 0.05.
Propensity score matching provides an alternative
means to balance study groups in order to reduce con-
founding when randomisation is not possible [16–20].
Logistic regression models were included to estimate the
propensity scores between the decreased and unchanged
HDL-C groups, with the HDL-C decrease as the response
variable and the following covariates: age, gender, baseline
HDL-C, baseline LDL-C, LDL-C change on statin treat-
ment, antihypertensive therapy, diagnosis of diabetes, heart
failure, hypertension, angina pectoris, peripheral artery
disease (PAD), and stroke.
The propensity scores were matched pairwise, with
exact matching for prior myocardial infarction and use of
calipers of width equal to 0.1 of the standard deviation of
the propensity score. The matching procedure was per-
formed using the Match function in the R package
Matching [21]. The primary endpoint was analysed by a
Cox proportional hazards model, using a grouped jack-
knife estimation of the variance to take the correlation
within pairs into account.
The association between HDL-C change and the pri-
mary endpoint in the decreased and increased HDL-C
groups was studied in the following sub groups: gender
(men/women), primary/secondary prevention, with/without
diabetes, and in patients above 75 years of age versus
younger patients. In the sub-group analyses, Cox regression
with adjustment for age, gender, baseline HDL-C, baseline
LDL-C, LDL-C change on statin treatment, antihyperten-
sive therapy, diagnoses of diabetes, heart failure, hyper-
tension, angina pectoris, PAD, and stroke was used.
An additional analysis was performed comparing the
separate outcome of cardiovascular death or all-cause
death, as well as a sensitivity analysis including patients
with a LDL-C reduction of\0.5 mmol/L.
3 Results
In all, 84,812 patients were initiated on statin treatment
during the observation period, of whom 15,357 (18 %)
were eligible (Fig. 1). The main reason for exclusion was
lack of recorded lipid measurements before and during
statin treatment. Compared with the study population, the
excluded patients were more often men, were older, and
fewer had diabetes/more had CVD before statin treatment
initiation (Table S1).
In the full eligible study cohort, baseline mean age was
62.7 years (range 19–85 years) and mean HDL-C was
1.48 mmol/L. The majority of patients (96 %) were initi-
ated on simvastatin, with a mean dose of 20 mg/day (me-
dian 20 mg/day). Of these patients, 20 % had a decrease in
HDL-C during the observation period, 58 % were
unchanged, and 22 % showed an increase (Fig. 1). The
patient group with a decrease in HDL-C comprised more
women, had a higher HDL-C at baseline (1.69 mmol/L),
less diabetes, compared with the unchanged HDL-C group
(Table 1). The groups were similar regarding presence of
cardiovascular diagnoses; myocardial infarction, angina
pectoris, PAD, stroke or heart failure. The changes in
HDL-C and LDL-C did not show any correlation (Fig. S1)
[10].
The decreased and unchanged HDL-C groups showed
a large degree of propensity score overlap (71 %),
indicating that these groups were similar prior to the
start of statin treatment. After matching, the decreased
and unchanged HDL-C groups had similar baseline
characteristics and LDL-C changes, with the exception
of a higher simvastatin dose and lower triglyceride level
in the decreased HDL-C group (Table 1). The mean
baseline HDL-C was 1.69 mmol/L and mean LDL-C was
4.53 mmol/L, respectively. The median time from HDL-
C measurement to the start of statin treatment was
12 days [interquartile range (IQR) 7–31 days], and the
mean time from the start of statin treatment to the sec-
ond HDL-C measurement was 84 days (IQR 48–148
days). Patients were followed for up to 7 years, with a
median follow-up of 2 years, including 14,198 patient-
years. In the group with decreased HDL-C, the mean
HDL-C reduction was 0.27 mmol/L. The primary end-
point incidence rates (per 1000 patient-years) were 12.8
and 8.2 in the decreased and unchanged HDL-C groups,
respectively.
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The risk of major cardiovascular events was 56 %
higher in the decreased HDL-C group compared with the
unchanged HDL-C group [hazard ratio (HR), 1.56; 95 %
confidence interval (CI), 1.12–2.16; p\ 0.01; Table 2;
Fig. 2]. The difference between the two groups was due to
ischaemic stroke (HR, 1.74; 95 % CI, 1.00–3.03;
p = 0.05), but was also driven by cardiovascular death
(HR, 1.72; 95 % CI, 0.86–3.42; p = 0.12).
3.1 Subgroup Analyses
The association between HDL-C change and the primary
endpoint in the decreased and increased HDL-C groups
showed consistent results in the sub-group analyses: gen-
der, primary/secondary prevention, with/without diabetes,
and in patients aged [75 years of age versus younger
patients (Fig. 3; Table 3).
No difference in risk of major cardiovascular events was
observed between the HDL-C increase group compared
with the unchanged HDL-C group (HR, 1.05; 95 % CI,
0.82–1.34; p = 0.72).
3.2 Sensitivity Analyses
The separate outcome of cardiovascular death (HR, 1.61;
95 % CI, 0.94–2.75; p = 0.09) and all-cause death (HR,
1.30; 95 % CI, 0.92–1.85; p = 0.14) showed similar
results. To assess the impact of the 3161 patients with an
LDL-C reduction of\0.5 mmol/L, they were included in
the analyses which showed a similar risk (HR, 1.56; 95 %
CI, 1.25–1.95; p\ 0.01).
4 Discussion
In this study, two-thirds of eligible patients initiating statin
treatment had a change in their HDL-C level, and the
degree of change was similar to that observed in ran-
domised clinical trials [10]. A paradoxical decrease in
HDL-C of [0.1 mmol/L was associated with a 56 %
increase in major adverse cardiovascular events compared
with unchanged HDL-C levels. The results were consistent
across subgroups based on age, gender, presence of dia-
betes, primary and secondary prevention. No association
between increased HDL-C levels and risk of major adverse
cardiovascular events could be observed.
Results from a recent meta-analysis did not demonstrate
an association between statin treatment, HDL-C change,
and CVD risk [11]. Our patients had a relatively high
untreated HDL-C level (1.48 mmol/L), in line with
observations of untreated HDL-C levels in other Scandi-
navian studies, but in contrast with the recent publications
[11, 21–23]. We observed a greater reduction in HDL-C
(-0.27 mmol/L) compared with the meta-analysis
(-0.13 mmol/L), and the relatively small HDL-C reduc-
tion in the meta-analysis might not have been sufficient to
detect CVD risk associations. Furthermore, our findings are
supported by a recent study which shows that a paradoxical
decrease in plasma HDL-C levels after statin therapy is an
important risk factor predicting long-term adverse cardiac
events in patients with acute myocardial infarction [12].
Low single point measurements of HDL-C levels in
patients receiving statin treatment have been reported to be
associated with increased CVD risk, irrespective of the low
84 812 patients starting statin treatment 2004-2009 
69 455 patients were excluded: 
• 1 674 patients were not  <18 or >86 years of age 
• 5 153 patients did not have 15 months of prior medical history available 
• 57 881 patients did not have HDL-C and LDL-C measurements prior to start 
and during statin treatment within one year pre and post statin initiation 
• 3 161 patients did not have a reduction in LDL-C of >0.5 mmol/L on statin 
treatment  
• 1 546 patients had a diagnosis of malignancy or alcoholism 
3 068 (20%) patients had a 
decrease in HDL-C of more 
than 0.1 mmol/L 
8 919 (58%) patients had no 
change in HDL-C 
 (± 0.1 mmol/L) 
3 370 (22%) patients had an 
increase in HDL-C of more 
than 0.1 mmol/L 
Fig. 1 Patient flow. HDL-C
high-density lipoprotein
cholesterol, LDL-C low-density
lipoprotein cholesterol
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LDL-C levels achieved [13]. We have shown that patients
with a relatively high HDL-C (mean 1.48 mmol/L) newly
initiated on cholesterol-modifying treatment (statin) and
who experienced a consecutive HDL-C reduction have an
increased cardiovascular risk, independently of baseline
LDL-C and LDL-C change on statin treatment. Our find-
ings are in line with previous observational data where a
threshold for increased cardiovascular risk for HDL-C
values below 1.3–4 mmol/L was observed [4]. Since the
untreated HDL-C is relatively high in our material, this is
the likely explanation for why we do not observe a reduced
cardiovascular risk with increased HDL-C values. A major
decrease in HDL-C level, independent of the size of the
LDL-C reduction, might cause a shift in cholesterol
transport. Indeed, the one-third of patients initiated on
statin therapy who had a paradoxical reduction in HDL-C
level [10] may have a suboptimal balance of cholesterol in/
out transport to/from the inner arterial wall. Other impor-
tant cardiovascular risk-lowering properties of HDL-C
include antioxidant, anti-apoptotic, anti-inflammatory,
antithrombotic, and anti-proteolytic properties, which
account for the direct protective action on endothelial cells
Table 1 Baseline characteristics for patients with a decrease in HDL-C (C0.1 mmol/L), an increase in HDL-C (C0.1 mmol/L), or no change in
HDL-C (±0.1 mmol/L) (unmatched and propensity score-matched populations)
Variable Unmatched population Propensity score-matched population
Decreased
(n = 3068)
Unchanged
(n = 8919)
Increased
(n = 3370)
Decreased
(n = 2975)
Unchanged
(n = 2975)
p valuea
Women, n (%) 1872 (61.0) 4840 (54.3) 1997 (59.3) 1803 (60.6) 1798 (60.4) 0.92
Age (years) 62.3 (10.2) 62.6 (10.2) 63.0 (9.8) 62.2 (10.1) 62.3 (10.2) 0.64
Simvastatin, n (%) 2925 (95.3) 8510 (95.4) 3244 (96.3) 2835 (95.3) 2823 (94.9) 0.09
Dose (mg) 20.8 (9.7) 19.7 (8.7) 20.2 (8.8) 20.8 (9.7) 19.7 (8.4) \0.01
Hospitalisations, number/year prior
to statin start
0.2 (0.6) 0.2 (0.6) 0.19 (0.6) 0.2 (0.6) 0.2 (0.6) 0.16
Systolic blood pressure (mmHg) 144.6 (19.8) 143.6 (18.6) 144.0 (18.9) 144.6 (19.8) 143.3 (19.0) 0.02
Diastolic blood pressure (mmHg) 82.6 (10.4) 82.0 (10.1) 82.0 (10.4) 82.7 (10.4) 81.9 (10.2) 0.01
Body mass index (kg/cm2) 28.6 (5.0) 29.4 (5.0) 28.8 (4.9) 28.7 (5.0) 28.6 (5.2) 0.67
HbA1c (%) 5.5 (1.3) 5.7 (1.3) 5.64 (1.4) 5.6 (1.3) 5.6 (1.4) 0.77
HDL-C (mol/L) 1.69 (0.47) 1.41 (0.40) 1.44 (0.42) 1.66 (0.43) 1.66 (0.45) 0.95
LDL-C (mmol/L) 4.53 (1.00) 4.45 (0.95) 4.52 (0.97) 4.53 (0.99) 4.52 (0.96) 0.71
Change in LDL-C (mmol/L) -1.96 (0.81) -1.84 (0.70) -1.86 (0.75) -1.95 (0.80) -1.96 (0.73) 0.92
Total cholesterol (mmol/L) 6.88 (1.10) 6.66 (1.04) 6.77 (1.07) 6.86 (1.09) 6.86 (1.05) 0.86
Triglycerides (mmol/L) 1.61 (0.45) 1.37 (0.38) 1.40 (0.40) 1.53 (0.75) 1.55 (0.75) 0.23
Antihypertensives (hypertension),
n (%)
1426 (46.5) 4320 (48.4) 1530 (45.4) 1379 (46.4) 1410 (47.4) 0.44
Diabetes, n (%) 691 (22.5) 2433 (27.3) 834 (24.8) 678 (22.8) 680 (22.9) 0.98
Myocardial infarction, n (%) 107 (3.5) 254 (2.9) 81 (2.4) 93 (3.1) 93 (3.1) 1.00
Unstable angina pectoris, n (%) 45 (1.5) 129 (1.5) 46 (1.4) 44 (1.5) 43 (1.5) 1.00
Heart failure, n (%) 75 (2.4) 237 (2.7) 75 (2.2) 73 (2.5) 72 (2.4) 1.00
Arrhythmia, n (%) 182 (5.9) 480 (5.4) 175 (5.2) 177 (6.0) 180 (6.1) 0.64
Peripheral arterial disease, n (%) 54 (1.8) 130 (1.5) 56 (1.7) 52 (1.8) 44 (1.5) 0.47
Cerebrovascular disease, n (%) 242 (7.9) 665 (7.5) 208 (6.2) 181 (6.1) 172 (5.8) 0.66
Values are expressed as mean (SD) unless specified otherwise
HbA1c glycated haemoglobin, HDL high-density lipoprotein cholesterol, LDL low-density lipoprotein cholesterol
a T test for continuous variables and Chi-square test for categorical variable
Table 2 Exposure time (years)
in the propensity score-matched
populations
Unchanged HDL-C Decreased HDL-C Total
Maximum follow-up time 6.9 6.9 6.9
Median follow-up time 1.9 2.0 2.0
Total patient-years 7157 7041 14,198
Total number of events 59 90 149
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[24]. The decrease in HDL-C might consequently nega-
tively impact these protective actions. However, we believe
that reduction of HDL-C per se is associated with increased
cardiovascular risk and not necessarily a statin-specific
effect. Thus, we would highlight the importance of non-
pharmacological efforts that will prevent HDL-C reduc-
tions, such as avoiding weight gain and/or maintaining
physical activity levels.
The endpoint was a composite of hospitalisation with a
primary diagnose of myocardial infarction, unstable angina
pectoris, or ischaemic stroke, or cardiovascular death. An
analysis of the separate endpoint components showed that
risk of ischaemic stroke was statistically significant. The
risks of coronary events and cardiovascular death were not
significant, although the trends showed indication of similar
directions/patterns. This finding might be somewhat sur-
prising, as a predominant effect of statin treatment on coro-
nary disease would be expected. However, as more patients
in Sweden die outside hospital owing to coronary disease
than owing to stroke, and a proportion of fatal coronary
events occur in the out-of-hospital setting, stroke events were
more likely to be a classified event in our study because more
of these patients survived to hospitals [25, 26]. Similar
results were observed when comparing outcome of separate
analysis of cardiovascular death with all-cause death. Inter-
estingly, the recent study which showed that a paradoxical
decrease in plasma HDL-C levels after statin therapy initi-
ation also had results driven by significantly higher incidence
of stroke in the decreased HDL-C group [12].
Fig. 2 Kaplan-Meier plot of time to first major cardiovascular events
for the decreased and unchanged HDL-C propensity score-matched
populations. MACE major adverse cardiovascular events
Fig. 3 Hazard ratio forest plot of major cardiovascular events in different sub-groups
230 P. Hasvold et al.
Eighteen percent of patients initiated on statin treatment
during the observation period were included in the study.
The main reason for exclusion was lack of laboratory data,
as only laboratory measurements from primary care were
available. This favoured the inclusion of patients with
regular healthcare controls (hypertension, diabetes, atrial
fibrillation) in primary care. A considerable proportion of
secondary prevention patients with initiation of statin
treatment in hospital did not have a pre-treatment HDL-C
measurement available to us and were therefore not
included (Table S1).
The exclusion of a significant proportion of patients
might call into question the generalisability of the results.
However, we found consistent results in all subgroup
analyses, with a numerically higher risk of reaching the
composite endpoint with decreased HDL-C levels for all
subgroups (older vs. younger patients, men vs. women,
primary vs. secondary prevention patients, and presence of
diabetes). However, among secondary preventive patients,
a smaller numerical difference in cardiovascular risk
between unchanged and decreased HDL-C groups was
observed. Secondary prevention, for patients recently
experiencing a myocardial infarction or a stroke, might
potentially a have an initial increased thrombotic risk,
which is more critical than the long-term effect caused by
the atherosclerosis process. Altogether, this indicates that
the study findings might be valid for a broad statin-treated
population.
A further potential limitation regarding generalisability
is the fact that the absolute majority of patients in Sweden
are treated with relatively low doses of simvastatin. The
frequent use of low-dose simvastatin might be the result of
a stringent reimbursement regime, only allowing the use of
high-potency statins in patients who do not reach treatment
goals or in individuals who do not tolerate simvastatin. The
effect on HDL-C change achieved by statins in general is
reported to be independent of the reduction in LDL-C [10].
The present study is observational and unmeasured
confounders may have influenced our results. Patients with
malignancy or history of alcoholism were not included in
the study. Changes in body weight, smoking pattern, or
physical activity might influence levels of HDL-C, the
latter two of which are not systematically recorded in pri-
mary care records. Since smoking previously was reported
to be associated with generally low HDL-C levels, it is
likely that smokers would be in the unchanged group or
increase group due to the regression to the mean effect in
our study [10, 27]. Furthermore, if the increase in HDL-C
was due to cessation of smoking, a decrease in HDL-C
should be found more frequently in smokers. In Sweden,
not only is the overall smoking practice low (\15 %) but
the likelihood of patients starting smoking during initiation
of statin therapy can also be considered to be low. Fur-
thermore, the effect of smoking cessation programmes in
primary care is modest [28, 29]. The inverse correlation
between physical activity and HDL-C change is low and
can therefore be considered to be of minor importance [30].
We did not observe a marked percentage increase in body
mass index in patients with a reduction in HDL-C, when
compared with patients with unchanged HDL-C levels.
Low compliance to statin treatment could potentially be
a possible explanation for our findings. However, patients
were only included in the analyses while on statin treat-
ment, and only if the reported LDL-C reduction was
[0.5 mmol/L. The risk of the results being due to low
compliance and/or statin response can therefore also be
considered to be low.
The statin prescription pattern might be a source of
confounding by indication. We found that patients with
high cardiovascular risk in general had a lower untreated
LDL-C, and vice versa. This correlation between LDL
levels and CVD risk has been reported previously in a real-
life clinical setting [31]. However, we found no correlation
between LDL-C change and HDL-C change, as also
Table 3 Events and events rates for forest plot (Fig. 3)
Unchanged
HDL-C
No of patients
Decreased
HDL-C
No of patients
Unchanged
HDL-C
No of events
Decreased
HDL-C
No of events
Unchanged
HDL-C
Events/1000
patient-years
Decreased
HDL-C
Events/1000
patient-years
Total 8919 3068 236 93 11.3 12.8
Female 4840 1872 98 43 8.5 9.7
Male 4079 1196 138 50 14.6 17.5
Primary prevention 5063 1838 62 34 5.3 8.1
Secondary prevention 3856 1230 174 59 18.8 19.0
Diabetes 2433 691 93 36 16.3 20.4
No diabetes 6486 2377 143 57 9.4 10.3
Age over 75 years 959 303 72 32 31.8 48.7
Age below 75 years 7960 2765 164 61 8.8 9.2
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supported by a previous report [10]. A prescription bias
based on low HDL-C levels might also be a source of
explanation for our findings. As low HDL-C is not a reason
for initiation of statin treatment in Sweden, though, it is not
likely that HDL-C should be affected by confounding by
indication. Furthermore, we observed a mean difference of
1.1 mg of simvastatin between the decrease and unchanged
groups after propensity score matching. We do not think
this minimal difference in dosing had any impact on the
results.
Laboratory data were only available from primary care
records. Biological and analytical variation of HDL-C
values may be a potential source of misclassification into
the different HDL-C change groups. However, we
observed similar associations with baseline cholesterol
parts [HDL-C, plasma triglycerides (TG), and LDL-C] on
HDL-C change pattern in our study compared to those
reported in randomized clinical trials [10]. Thus, in our
study, patients with high HDL-C had higher likelihood of
HDL-C reduction and patients with low HDL-C and higher
associated cardiovascular risk at baseline would more
likely be identified for the HDL-C decrease group. In
Sweden, HDL-C samples are generally analysed at regional
central laboratories, all of which have participated in
national quality and standardisation programmes since the
end of the 1980s [32]. The analytical variation for HDL-C
in the Swedish external quality assurance programme is
between 3 % and 4 % (at the level of 1.68 mmol/L) [31],
while the biological variation of HDL-C is approximately
7 %. Patients in our study had to have a decrease in HDL-C
of [0.1 mmol/L, and the average HDL-C decrease was
0.27 mmol/L. Our conservative estimations of the HDL-C
variation support the notion that the magnitude of the
observed HDL-C decrease was sufficient.
The present study also has several important strengths.
First, the composite endpoint has been validated previously
in Swedish studies [19]. Second, only statin-naı¨ve patients
were included in order to increase the likelihood of analysing
the actual treatment effect on HDL-C levels. The observed
HDL-C change pattern is similar to that observed in ran-
domised clinical trials [10]. Third, our analyses carefully
matched the patients for numerous cardiovascular diagnoses,
risk factors, including baseline LDL-C, and LDL-C change
on treatment, thus increasing the likelihood of similar
baseline risk. Finally, using Swedish national health registers
the follow-up was performed with basically no loss of events.
5 Conclusions
A marked proportion of patients newly initiated on statin
treatment experienced a decrease in HDL-C. This decrease
was associated with a higher risk of major adverse
cardiovascular events compared with patients in whom
HDL-C levels were unchanged. Statin-induced increase in
HDL-C was not associated with lower risk of major
adverse cardiovascular events.
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